Kutane Lymphome

Bunn PA Jr, Hoffann SJ, Norris D et al. (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121: 592–602 Dummer R (2005) Emerging drugs in cutaneous T-cell lymphomas. Expert Opin 10: 381–392 Dummer R, Kempf W, Hess Schmid M et al. (2003) Therapy of cutaneous lymphoma – current practice an future development. Onkologie 26: 366–72 Dummer R, Stadler R, Sterry W (2005) Deutsche Leitlinie: Kutane Lymphome. In: Garbe C (Hrsg) Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Georg Thieme, Stuttgart, S 83–95 Duvic M, Hymes K, Heald P et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J Clin Oncol 19: 2456–2471 Faderl S, Coutre S, Byrd JC et al. (2005) The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19: 2147–2152 Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4: 180–188 Foss F (2003) Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymph 44 [Suppl 3]: S55–61 Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106: 454–457 Jacobs SA, Foon KA (2005) Monoclonal antibody therapy of leukemias and lymphomas. Expert Opin Biol Ther 5: 1225–1243 Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissue. IARC Press, Lyon Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287–299 Kaye FJ, Bunn PA Jr, Steinberg SM et al. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321: 1784–1790 Kim EJ, Hess S, Richardson SK et al. (2005) Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest 115: 798–812 Knobler R, Girardi M (2001) Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphomas. Ann NY Acad Sci 94: 123–138 Olsen E, Duvic M, Frankel A et al. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19: 376–388 Piekarz RL, Robey R, Sandor V et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901288), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865–2868 Querfeld C, Rosen ST, Kuzel TM et al. (2005) Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141: 305–311 Rupoli S, Goteri G, Pulini S et al. (2005) Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides. Eur J Haematol 75: 136–145 Schon MP, Schon M (2004) Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9: 291–298 Stadler R (1998) Interferons in dermatology – present-day standard. Dermatol Clin 16: 377–398 Stadler R, Kremer A (2006) Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin Oncol 33 [1 Suppl 3]: S7–10 Stadler R, Otte HG (1997) Aktuelle Behandlungsstrategien kutaner Lymphome. Zeitschr Hautk H+G 72: 257–262 Stadler R, Otte HG, Luger T et al. (1998) Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus intferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma, stages I and II. Blood 92: 3578–3581 Trautinger F, Knobler R, Willemze R et al. (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 42: 1014–1030 Urosevic M, Dummer R, Contrad C et al. (2005) Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod. J Nat Cancer Inst 15: 1143–1153 van Dognen JJ, Langerak AW, Bruggemann M et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 17: 2257–2317 Vonderheid EC, Berengo MG, Burg G et al. (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46: 95–106 Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768–3785 Willemze R, Kerl H, Sterry W et al. (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of th European Organization for Research and Treatment of Cancer. Blood 90: 354–371 Wollina U, Dummer R, Brockmeyer NH et al. (2003) Multicenter study of pegylated liposomal docorubicin in patients with cutaneous T-cell lymphoma. Cancer 98: 993–1001